Other drug targets of the PI3K signaling pathway have been related with SLE or other SLE-like disorders, such as CDK inhibitors, recently proposed to be used for treatment of some autoimmune disorders [19], or inhibitors of the mitogen-activated protein kinase (MAPK) signaling pathway [20]. This evidence concerns the gene WNK2 and autoimmune disease.